Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

L. W. Seymour, K. Ulbrich, Peter Steyger, M. Brereton, V. Subr, J. Strohalm, R. Duncan

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 μg h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 μg h g-1. and for total doxorubicin (i.e. free plus conjugated) of 149.1 μg h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 μ h g-1. and 671.7 μg h g-1. for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.1- to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133% using aggressive regimens of free doxorubicin (3 × 5 mg kg-1).

Original languageEnglish (US)
Pages (from-to)636-641
Number of pages6
JournalBritish Journal of Cancer
Volume70
Issue number4
StatePublished - Oct 1994
Externally publishedYes

Fingerprint

Tropism
Prodrugs
Doxorubicin
Melanoma
Polymers
Neoplasms
Area Under Curve
Therapeutics
Fluorescein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. / Seymour, L. W.; Ulbrich, K.; Steyger, Peter; Brereton, M.; Subr, V.; Strohalm, J.; Duncan, R.

In: British Journal of Cancer, Vol. 70, No. 4, 10.1994, p. 636-641.

Research output: Contribution to journalArticle

Seymour, L. W. ; Ulbrich, K. ; Steyger, Peter ; Brereton, M. ; Subr, V. ; Strohalm, J. ; Duncan, R. / Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. In: British Journal of Cancer. 1994 ; Vol. 70, No. 4. pp. 636-641.
@article{a5fd53bb15b34c048fc02b2252958eaa,
title = "Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma",
abstract = "Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 μg h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 μg h g-1. and for total doxorubicin (i.e. free plus conjugated) of 149.1 μg h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 μ h g-1. and 671.7 μg h g-1. for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.1- to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320{\%} (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133{\%} using aggressive regimens of free doxorubicin (3 × 5 mg kg-1).",
author = "Seymour, {L. W.} and K. Ulbrich and Peter Steyger and M. Brereton and V. Subr and J. Strohalm and R. Duncan",
year = "1994",
month = "10",
language = "English (US)",
volume = "70",
pages = "636--641",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

AU - Seymour, L. W.

AU - Ulbrich, K.

AU - Steyger, Peter

AU - Brereton, M.

AU - Subr, V.

AU - Strohalm, J.

AU - Duncan, R.

PY - 1994/10

Y1 - 1994/10

N2 - Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 μg h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 μg h g-1. and for total doxorubicin (i.e. free plus conjugated) of 149.1 μg h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 μ h g-1. and 671.7 μg h g-1. for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.1- to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133% using aggressive regimens of free doxorubicin (3 × 5 mg kg-1).

AB - Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 μg h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 μg h g-1. and for total doxorubicin (i.e. free plus conjugated) of 149.1 μg h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 μ h g-1. and 671.7 μg h g-1. for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.1- to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133% using aggressive regimens of free doxorubicin (3 × 5 mg kg-1).

UR - http://www.scopus.com/inward/record.url?scp=0028030559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028030559&partnerID=8YFLogxK

M3 - Article

C2 - 7917909

AN - SCOPUS:0028030559

VL - 70

SP - 636

EP - 641

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -